The phase 2 study compared the combination of tepotinib plus gefitinib to standard platinum-based chemotherapy in patients who are EGFR-mutant and T790M-negative, with MET overexpression (IHC2+ or IHC3+) and/or amplification (FISH GCN ≥ 5 or MET–CEP7 ratio ≥ 2) in advanced or metastatic NSCLC patients who progressed on first- or second-generation EGFR TKIs [58]. The gene discussed is MET; the disease is non-small cell lung carcinoma.